JP2006523664A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006523664A5 JP2006523664A5 JP2006506137A JP2006506137A JP2006523664A5 JP 2006523664 A5 JP2006523664 A5 JP 2006523664A5 JP 2006506137 A JP2006506137 A JP 2006506137A JP 2006506137 A JP2006506137 A JP 2006506137A JP 2006523664 A5 JP2006523664 A5 JP 2006523664A5
- Authority
- JP
- Japan
- Prior art keywords
- soft tissue
- thorium
- kbq
- medicament according
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000016247 Soft tissue disease Diseases 0.000 claims description 10
- ZSLUVFAKFWKJRC-FTXFMUIASA-N thorium-227 Chemical compound [227Th] ZSLUVFAKFWKJRC-FTXFMUIASA-N 0.000 claims description 10
- 206010028980 Neoplasm Diseases 0.000 claims description 7
- 210000004872 soft tissue Anatomy 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 210000001519 tissue Anatomy 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 238000011282 treatment Methods 0.000 claims description 3
- 201000009030 Carcinoma Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 12
- HCWPIIXVSYCSAN-OIOBTWANSA-N radium-223 Chemical compound [223Ra] HCWPIIXVSYCSAN-OIOBTWANSA-N 0.000 claims 5
- 229960005562 radium-223 Drugs 0.000 claims 5
- 230000037396 body weight Effects 0.000 claims 4
- 229940014144 folate Drugs 0.000 claims 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims 4
- 235000019152 folic acid Nutrition 0.000 claims 4
- 239000011724 folic acid Substances 0.000 claims 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 3
- 239000008139 complexing agent Substances 0.000 claims 3
- 231100001180 nonmyelotoxic Toxicity 0.000 claims 3
- 208000032383 Soft tissue cancer Diseases 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- 239000002502 liposome Substances 0.000 claims 2
- 230000003211 malignant effect Effects 0.000 claims 2
- 230000008685 targeting Effects 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 238000002512 chemotherapy Methods 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 231100000052 myelotoxic Toxicity 0.000 claims 1
- 230000002556 myelotoxic effect Effects 0.000 claims 1
- 230000001599 osteoclastic effect Effects 0.000 claims 1
- 230000002188 osteogenic effect Effects 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 238000011362 radionuclide therapy Methods 0.000 claims 1
- 238000009168 stem cell therapy Methods 0.000 claims 1
- 238000009580 stem-cell therapy Methods 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0308731.9A GB0308731D0 (en) | 2003-04-15 | 2003-04-15 | Method of radiotherapy |
| GB0308731.9 | 2003-04-15 | ||
| PCT/GB2004/001654 WO2004091668A1 (en) | 2003-04-15 | 2004-04-15 | Thorium-227 for use in radiotherapy of soft tissue disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011265169A Division JP5468597B2 (ja) | 2003-04-15 | 2011-12-02 | 軟組織疾患の放射線治療におけるトリウム−２２７を用いた医薬組成物、複合体及びその調製方法、並びにキット |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006523664A JP2006523664A (ja) | 2006-10-19 |
| JP2006523664A5 true JP2006523664A5 (cg-RX-API-DMAC10.html) | 2012-02-09 |
| JP5006032B2 JP5006032B2 (ja) | 2012-08-22 |
Family
ID=35385222
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006506137A Expired - Lifetime JP5006032B2 (ja) | 2003-04-15 | 2004-04-15 | 軟組織疾患の放射線治療におけるトリウム−２２７の使用 |
| JP2011265169A Expired - Lifetime JP5468597B2 (ja) | 2003-04-15 | 2011-12-02 | 軟組織疾患の放射線治療におけるトリウム−２２７を用いた医薬組成物、複合体及びその調製方法、並びにキット |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011265169A Expired - Lifetime JP5468597B2 (ja) | 2003-04-15 | 2011-12-02 | 軟組織疾患の放射線治療におけるトリウム−２２７を用いた医薬組成物、複合体及びその調製方法、並びにキット |
Country Status (18)
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100586484C (zh) * | 2003-04-15 | 2010-02-03 | 艾尔格塔公司 | 用于放射治疗软组织疾病的钍-227 |
| GB201002508D0 (en) * | 2010-02-12 | 2010-03-31 | Algeta As | Product |
| GB201007354D0 (en) * | 2010-04-30 | 2010-06-16 | Algeta Asa | Method |
| GB201105298D0 (en) * | 2011-03-29 | 2011-05-11 | Algeta Asa | Pharmaceutical preparation |
| GB201600154D0 (en) * | 2016-01-05 | 2016-02-17 | Bayer As | Isotope preparation method |
| GB201600153D0 (en) * | 2016-01-05 | 2016-02-17 | Bayer As | Isotope preparation method |
| EP3554257B1 (en) | 2016-12-15 | 2023-07-12 | Société des Produits Nestlé S.A. | Compositions and methods that modulate white blood cells or neutrophils in a companion animal |
| FR3088769B1 (fr) * | 2018-11-15 | 2020-12-25 | Orano Med | Procede de preparation d'au moins un generateur a haute teneur en radium-228 |
| RU2767567C1 (ru) * | 2020-10-27 | 2022-03-17 | Станислав Анатольевич Дороватовский | Комплексные соединения, содержащие в своем составе радионуклид 227Th, а также бисфосфонатный фрагмент, способы их получения, а также потенциальное применение в качестве действующего вещества в составе остеотропного радиофармацевтического лекарственного препарата |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0429624T3 (da) * | 1989-06-19 | 1994-05-30 | Akzo Nobel Nv | Radioimmunterapi under anvendelse af alfa-partikelemission |
| JPH07505886A (ja) * | 1992-04-13 | 1995-06-29 | ザ ダウ ケミカル カンパニー | マクロ環状キレート化剤の製造方法及びキレートの形成並びにその結合体 |
| CN1073860C (zh) * | 1998-08-20 | 2001-10-31 | 中国核动力研究设计院 | 用于骨肿瘤治疗或诊断的放射性药物药盒的制备方法 |
| MY133346A (en) * | 1999-03-01 | 2007-11-30 | Biogen Inc | Kit for radiolabeling ligands with yttrium-90 |
| NO314537B1 (no) * | 1999-12-06 | 2003-04-07 | Anticancer Therapeutic Inv Sa | Reseptorbindende konjugater |
| NO312708B1 (no) * | 2000-02-21 | 2002-06-24 | Anticancer Therapeutic Inv Sa | Radioaktive liposomer til terapi |
| AU4906901A (en) * | 2000-02-25 | 2001-09-17 | Dangshe Ma | Actinium-225 complexes and conjugates for radioimmunotherapy |
| NO313180B1 (no) * | 2000-07-04 | 2002-08-26 | Anticancer Therapeutic Inv Sa | Bensökende alfapartikkel emitterende radiofarmasöytika |
| ITMI20022411A1 (it) * | 2002-11-14 | 2004-05-15 | Bracco Imaging Spa | Agenti per la diagnosi e la terapia di tumori che espongono sulla superficie delle cellule proteine alterate. |
| CN100586484C (zh) * | 2003-04-15 | 2010-02-03 | 艾尔格塔公司 | 用于放射治疗软组织疾病的钍-227 |
-
2004
- 2004-04-15 CN CN200480016329A patent/CN100586484C/zh not_active Expired - Lifetime
- 2004-04-15 ES ES04727587.0T patent/ES2486845T3/es not_active Expired - Lifetime
- 2004-04-15 PL PL04727587T patent/PL1617876T3/pl unknown
- 2004-04-15 BR BRPI0409387A patent/BRPI0409387B8/pt not_active IP Right Cessation
- 2004-04-15 EP EP04727587.0A patent/EP1617876B1/en not_active Expired - Lifetime
- 2004-04-15 NZ NZ606996A patent/NZ606996A/en not_active IP Right Cessation
- 2004-04-15 KR KR1020057019497A patent/KR20060015507A/ko not_active Ceased
- 2004-04-15 ZA ZA200507983A patent/ZA200507983B/en unknown
- 2004-04-15 PT PT47275870T patent/PT1617876E/pt unknown
- 2004-04-15 EA EA200501456A patent/EA008195B1/ru not_active IP Right Cessation
- 2004-04-15 MX MXPA05010804A patent/MXPA05010804A/es active IP Right Grant
- 2004-04-15 DK DK04727587.0T patent/DK1617876T3/da active
- 2004-04-15 KR KR1020117003862A patent/KR101274867B1/ko not_active Expired - Lifetime
- 2004-04-15 CA CA2522148A patent/CA2522148C/en not_active Expired - Lifetime
- 2004-04-15 NZ NZ595758A patent/NZ595758A/xx not_active IP Right Cessation
- 2004-04-15 AU AU2004229218A patent/AU2004229218B2/en not_active Expired
- 2004-04-15 JP JP2006506137A patent/JP5006032B2/ja not_active Expired - Lifetime
- 2004-04-15 NZ NZ543044A patent/NZ543044A/en not_active IP Right Cessation
-
2005
- 2005-09-28 IL IL171148A patent/IL171148A/en active IP Right Grant
- 2005-11-15 NO NO20055390A patent/NO332931B1/no unknown
-
2011
- 2011-12-02 JP JP2011265169A patent/JP5468597B2/ja not_active Expired - Lifetime
-
2014
- 2014-07-28 CY CY20141100569T patent/CY1115407T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5642892B2 (ja) | 多形膠芽腫の治療のためのマシテンタンを含有する組み合わせ剤 | |
| Poen et al. | Chemo-radiotherapy for localized pancreatic cancer: increased dose intensity and reduced acute toxicity with concomitant radiotherapy and protracted venous infusion 5-fluorouracil | |
| JP2006523664A5 (cg-RX-API-DMAC10.html) | ||
| CA2522148A1 (en) | Thorium-227 for use in radiotherapy of soft tissue disease | |
| CN101155600B (zh) | 放射线治疗增强剂 | |
| RU2415670C2 (ru) | Усиливающий агент для радиационной терапии, включающий производное пиридина в качестве активного ингредиента | |
| Collier et al. | Doxorubicin hydrochloride, cyclophosphamide, and 5-fluorouracil combination in advanced prostate and transitional cell carcinoma | |
| Kim et al. | Phase II study with a combination of epirubicin, cisplatin, UFT, and leucovorin in advanced hepatocellular carcinoma | |
| Kies et al. | Chemotherapy of head and neck cancer | |
| NZ513872A (en) | Radioactive cisplatin in the treatment of cancer | |
| RU2005132175A (ru) | Комбинированное лечение опухолей, включающее неморубицин и лучевую терапию | |
| JP2005512996A (ja) | 乳癌の治療 | |
| Zaniboni et al. | Cyclophosphamide, epirubicin, high-dose folinic acid and 5-fluorouracil (super-FEC) as first-line chemotherapy for advanced breast cancer: preliminary results | |
| Cristofanilli et al. | Phase I/II trial of high dose mitoxantrone in metastatic breast cancer: the MD Anderson Cancer Center experience | |
| US20230226209A1 (en) | Antibody endohedral metallofullerene conjugate and uses thereof | |
| EP1545709B1 (en) | Neoadjuvant treatment of breast cancer | |
| JPS6337767B2 (cg-RX-API-DMAC10.html) | ||
| Galmarini et al. | Oral ftorafur plus intramuscular thiotepa as adjuvant chemotherapy in patients with breast cancer | |
| KR20230111070A (ko) | 라나토사이드 c를 포함하는 암의 방사면역치료 보조제 | |
| US20030228253A1 (en) | Radiolabelled thioplatin, compositions thereof and methods of cancer treatment | |
| CN101155782A (zh) | 以吡啶衍生物为有效成分的放射线治疗增强剂 | |
| EP1599210A1 (en) | A combined therapy comprising an indolopyrrolocarbazole derivative and another antitumor agent | |
| Midgley et al. | 7 Adjuvant therapy | |
| HK1118704B (en) | Radiotherapy enhancer | |
| HK1118807B (en) | Potentiator for radiation therapy comprising pyridine derivative as active ingredient |